Tag archive for ‘.Delay in Quick Shot Testosterone Clinical Trials’
Delay in Quick Shot Testosterone Clinical Program is Not a Major Setback for the Stock (ATRS, Buy, $2.53)
Antares sent out a press release today about a new development in the Quick Shot Testosterone phase 3 program. The Company said that based on a single reported occurrence of hives in the completed phase 2 study, which the FDA characterized as an apparent allergic reaction. The agency is recommending that the Company create a larger […]